Commercial Physical & Biological Research Industry - SEC Form 4 Insider Trading Screener
Services Sector - Engineering, Accounting, Research, Management Services - Commercial Physical & Biological Research
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2018-09-19 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | S - Sale | $59.31 | -114,983 | 9,030,527 | -1% | -$6,819,261 | |||||
| M | 2018-09-19 | MEDP | Medpace Holdings, Inc. | Troendle August J. | Pres, CEO, 10% | S - Sale | $59.31 | -114,983 | 9,392,378 | -1% | -$6,819,138 | |||||
| D | 2018-09-21 | NRCI | National Research Corp | Berwick Donald M | Dir | S - Sale+OE | $38.20 | -229 | 0 | -100% | -$8,748 | |||||
| DM | 2018-09-18 | NRC | National Research Corp | Karas Kevin R | SVP Finance, CFO, Treas, Secy | S - Sale+OE | $39.53 | -4,800 | 15,316 | -24% | -$189,738 | |||||
2018-09-18 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $40.00 | -1,451 | 5,381,998 | 0% | -$58,040 | ||||||
| DM | 2018-09-06 | NRCI | National Research Corp | Berwick Donald M | Dir | S - Sale+OE | $38.79 | -17,137 | 229 | -99% | -$664,717 | |||||
2018-09-17 | SNMX | Senomyx Inc | Senvest Management, LLC | 10% | S - Sale | $1.48 | -2,689,504 | 3,663,101 | -42% | -$3,967,825 | ||||||
2018-09-14 | BASI | Bioanalytical Systems Inc | Kissinger Peter | 10% | P - Purchase | $1.74 | +10,000 | 1,881,677 | +1% | +$17,382 | ||||||
2018-09-14 | BASI | Bioanalytical Systems Inc | Neff R Matthew | Dir | P - Purchase | $1.66 | +2,500 | 15,000 | +20% | +$4,150 | ||||||
2018-09-14 | PIRS | Pieris Pharmaceuticals, Inc. | Kiritsy Christopher P | Dir | P - Purchase | $5.11 | +5,000 | 10,000 | +100% | +$25,525 | ||||||
2018-09-13 | IQV | Iqvia Holdings Inc. | Danhakl John G | Dir | S - Sale | $126.47 | -413,233 | 134,440 | -75% | -$52,263,088 | ||||||
| DM | 2018-09-12 | SRNE | Sorrento Therapeutics, Inc. | Abg Management Ltd | 10% | S - Sale+OE | $5.02 | -297,568 | 6,791,335 | -4% | -$1,492,723 | |||||
| M | 2018-09-11 | IQV | Iqvia Holdings Inc. | Danhakl John G | Dir | S - Sale | $124.83 | -370,470 | 576,984 | -39% | -$46,244,717 | |||||
2018-09-11 | BASI | Bioanalytical Systems Inc | Downing Philip A | SVP, Preclinical Srvcs. | P - Purchase | $1.67 | +5,000 | 20,765 | +32% | +$8,350 | ||||||
| A | 2018-09-07 | IQV | Iqvia Holdings Inc. | Danhakl John G | Dir | S - Sale | $126.63 | -221,900 | 3,154,267 | -7% | -$28,099,197 | |||||
| D | 2018-09-07 | IQV | Iqvia Holdings Inc. | Knightly Kevin C | See Remarks | S - Sale+OE | $126.46 | -9,216 | 19,323 | -32% | -$1,165,455 | |||||
2018-09-07 | IQV | Iqvia Holdings Inc. | Danhakl John G | Dir | S - Sale | $126.63 | -221,900 | 3,154,267 | -7% | -$28,099,197 | ||||||
| D | 2018-09-04 | EXEL | Exelixis, Inc. | Schwab Gisela | Pres Prod Dev, Med Aff, CMO | S - Sale+OE | $18.53 | -22,500 | 342,793 | -6% | -$416,925 | |||||
| DM | 2018-09-04 | NRCI | National Research Corp | Berwick Donald M | Dir | S - Sale+OE | $39.03 | -5,263 | 17,366 | -23% | -$205,400 | |||||
| D | 2018-09-04 | INCY | Incyte Corp | Swain Paula J | EVP, HR | S - Sale+OE | $73.21 | -10,000 | 32,324 | -24% | -$732,100 | |||||
2018-09-04 | CRL | Charles River Laboratories International Inc | Kochevar Deborah Turner | Dir | S - Sale | $123.66 | -4,066 | 6,424 | -39% | -$502,799 | ||||||
2018-08-30 | HPPI | Hedgepath Pharmaceuticals, Inc. | Hasara Garrison J. | CFO, Treasurer | S - Sale | $0.27 | -100,000 | 3,959,044 | -2% | -$27,000 | ||||||
| D | 2018-08-28 | NRCI | National Research Corp | Berwick Donald M | Dir | S - Sale+OE | $39.42 | -600 | 22,629 | -3% | -$23,650 | |||||
2018-08-28 | EXAS | Exact Sciences Corp | Wyzga Michael S | Dir | S - Sale | $74.85 | -2,468 | 9,112 | -21% | -$184,730 | ||||||
| M | 2018-08-24 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $40.00 | -14,485 | 5,383,449 | 0% | -$579,400 | |||||
2018-08-27 | MEDP | Medpace Holdings, Inc. | Medpace Limited Partnership | 10% | S - Sale | $54.75 | -5,224,997 | 0 | -100% | -$286,068,586 | ||||||
| M | 2018-08-22 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.14 | -161,749 | 4,397,934 | -4% | -$6,168,842 | |||||
| D | 2018-08-20 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $17.82 | -90,000 | 318,705 | -22% | -$1,604,216 | |||||
| D | 2018-08-21 | INCY | Incyte Corp | Swain Paula J | EVP, HR | S - Sale+OE | $70.00 | -10,000 | 32,324 | -24% | -$700,000 | |||||
| M | 2018-08-17 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.03 | -38,480 | 5,559,683 | -1% | -$1,463,503 | |||||
| D | 2018-08-15 | EXEL | Exelixis, Inc. | Marchesi Vincent T | Dir | S - Sale+OE | $19.50 | -40,000 | 133,850 | -23% | -$780,000 | |||||
| M | 2018-08-13 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.05 | -41,393 | 5,598,163 | -1% | -$1,574,900 | |||||
| D | 2018-08-13 | CRL | Charles River Laboratories International Inc | Smith David Ross | Corporate EVP, CFO | S - Sale+OE | $120.06 | -1,249 | 12,441 | -9% | -$149,948 | |||||
| M | 2018-08-09 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.00 | -4,364 | 5,639,556 | 0% | -$165,832 | |||||
2018-08-09 | PRAH | Pra Health Sciences, Inc. | Kkr Pra Investors L.P. | 10% | S - Sale | $101.01 | -6,500,000 | 6,695,984 | -49% | -$656,565,000 | ||||||
2018-08-09 | SYNH | Syneos Health, Inc. | Thomas H. Lee Advisors, LLC | 10% | S - Sale | $49.73 | -6,000,000 | 19,252,226 | -24% | -$298,380,000 | ||||||
2018-08-09 | SYNH | Syneos Health, Inc. | Thomas H. Lee Advisors, LLC | 10% | S - Sale | $49.73 | -6,000,000 | 19,252,226 | -24% | -$298,380,000 | ||||||
2018-08-10 | MEDP | Medpace Holdings, Inc. | Medpace Limited Partnership | 10% | S - Sale | $54.35 | -5,175,000 | 5,224,997 | -50% | -$281,261,250 | ||||||
| DM | 2018-08-07 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $21.04 | -234,267 | 318,705 | -42% | -$4,928,523 | |||||
2018-08-07 | MEDP | Medpace Holdings, Inc. | Troendle August J. | Pres, CEO, 10% | S - Sale | $57.06 | -138,105 | 9,507,361 | -1% | -$7,880,271 | ||||||
2018-08-06 | EXEL | Exelixis, Inc. | Haley Patrick J. | SVP, Commercial | S - Sale | $20.92 | -2,361 | 158,735 | -1% | -$49,392 | ||||||
| M | 2018-08-06 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.00 | -56,334 | 5,643,920 | -1% | -$2,140,734 | |||||
| A | 2018-08-02 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.00 | -7,361 | 5,700,254 | 0% | -$279,718 | |||||
| M | 2018-08-02 | MEDP | Medpace Holdings, Inc. | Troendle August J. | Pres, CEO, 10% | S - Sale | $59.26 | -731,460 | 9,645,466 | -7% | -$43,344,976 | |||||
2018-08-02 | MEDP | Medpace Holdings, Inc. | Geiger Jesse J | CFO, COO, Lab Operations | S - Sale | $60.15 | -7,407 | 0 | -100% | -$445,531 | ||||||
2018-08-02 | IQV | Iqvia Holdings Inc. | Parks Robert | SVP, Controller | S - Sale | $124.34 | -871 | 1,195 | -42% | -$108,304 | ||||||
| D | 2018-08-01 | EXEL | Exelixis, Inc. | Schwab Gisela | Pres Prod Dev, Med Aff, CMO | S - Sale+OE | $20.56 | -22,500 | 292,793 | -7% | -$462,600 | |||||
| M | 2018-07-31 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.00 | -12,490 | 5,703,520 | 0% | -$474,644 | |||||
2018-07-30 | EXAS | Exact Sciences Corp | Zanotti Katherine S | Dir | S - Sale | $58.86 | -2,847 | 106,197 | -3% | -$167,574 | ||||||
2018-07-30 | EXAS | Exact Sciences Corp | Fallon John A. | Dir | S - Sale | $58.86 | -2,373 | 33,767 | -7% | -$139,675 | ||||||
2018-07-30 | EXAS | Exact Sciences Corp | Doyle James Edward | Dir | S - Sale | $58.86 | -1,318 | 37,093 | -3% | -$77,577 | ||||||
2018-07-30 | EXAS | Exact Sciences Corp | Carey Thomas D. | Dir | S - Sale | $58.86 | -3,427 | 48,983 | -7% | -$201,713 | ||||||
| D | 2018-07-30 | EXAS | Exact Sciences Corp | Elliott Jeffrey Thomas | CFO | S - Sale+OE | $57.78 | -8,984 | 33,237 | -21% | -$519,096 | |||||
| D | 2018-07-26 | IQV | Iqvia Holdings Inc. | Bousbib Ari | See Remarks | S - Sale+OE | $122.09 | -368,640 | 1,331,519 | -22% | -$45,007,258 | |||||
| D | 2018-07-26 | IQV | Iqvia Holdings Inc. | Rittenmeyer Ronald A | Dir | S - Sale+OE | $122.41 | -7,680 | 59,307 | -11% | -$940,109 | |||||
| D | 2018-07-24 | CRL | Charles River Laboratories International Inc | Molho Davide | Pres, COO | S - Sale+OE | $125.00 | -18,773 | 57,903 | -24% | -$2,346,625 | |||||
2018-07-23 | CRL | Charles River Laboratories International Inc | Molho Davide | Pres, COO | S - Sale | $125.00 | -11,600 | 62,827 | -16% | -$1,450,000 | ||||||
| D | 2018-07-18 | XON | Intrexon Corp | Sabzevari Helen | Pres, Precigen, Inc. | S - Sale+OE | $14.54 | -8,402 | 16,598 | -34% | -$122,165 | |||||
| D | 2018-07-17 | CRL | Charles River Laboratories International Inc | Molho Davide | Pres, COO | S - Sale+OE | $120.00 | -11,126 | 74,427 | -13% | -$1,335,120 | |||||
| D | 2018-07-16 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale+OE | $3.40 | -39,497 | 2,164,330 | -2% | -$134,290 | |||||
2018-07-17 | CRL | Charles River Laboratories International Inc | Girshick Birgit | Corporate EVP | S - Sale | $119.90 | -3,978 | 18,999 | -17% | -$476,962 | ||||||
| D | 2018-07-16 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $21.13 | -90,000 | 318,705 | -22% | -$1,901,700 | |||||
| AM | 2018-07-06 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.00 | -6,994 | 5,716,010 | 0% | -$265,772 | |||||
| M | 2018-07-06 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.00 | -6,994 | 5,716,010 | 0% | -$265,772 | |||||
2018-07-09 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $3.40 | -8,955 | 2,044,730 | 0% | -$30,447 | ||||||
| D | 2018-07-09 | INCY | Incyte Corp | Swain Paula J | EVP, HR | S - Sale+OE | $71.11 | -10,000 | 32,963 | -23% | -$711,100 | |||||
2018-07-09 | INCY | Incyte Corp | Iyengar Vijay K | EVP GPS, BD, Licensing | S - Sale | $71.34 | -606 | 8,103 | -7% | -$43,232 | ||||||
| M | 2018-07-06 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.00 | -6,994 | 5,716,010 | 0% | -$265,772 | |||||
2018-07-03 | XON | Intrexon Corp | Kirk Randal J | CEO, 10% | P - Purchase | $13.37 | +7,479,431 | 66,789,237 | +13% | +$99,999,992 | ||||||
| M | 2018-07-03 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.00 | -7,719 | 5,723,004 | 0% | -$293,347 | |||||
2018-07-02 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $111.55 | -2,775 | 322,178 | -1% | -$309,540 | ||||||
2018-07-02 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $111.34 | -5,348 | 274,451 | -2% | -$595,462 | ||||||
2018-07-02 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $111.11 | -5,471 | 279,799 | -2% | -$607,865 | ||||||
2018-07-02 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $110.80 | -5,005 | 285,270 | -2% | -$554,552 | ||||||
2018-07-02 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $110.53 | -6,401 | 290,275 | -2% | -$707,472 | ||||||
| D | 2018-07-02 | EXEL | Exelixis, Inc. | Schwab Gisela | Pres Prod Dev, Med Aff, CMO | S - Sale+OE | $21.20 | -22,500 | 292,793 | -7% | -$477,000 | |||||
| D | 2018-07-02 | EXAS | Exact Sciences Corp | Coward D Scott | SVP, GC | S - Sale+OE | $59.10 | -2,135 | 77,048 | -3% | -$126,176 | |||||
| D | 2018-06-25 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $19.62 | -90,000 | 318,705 | -22% | -$1,765,800 | |||||
| M | 2018-06-25 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.01 | -15,358 | 5,730,723 | 0% | -$583,762 | |||||
2018-06-25 | CRL | Charles River Laboratories International Inc | Massaro George | Dir | S - Sale | $115.55 | -300 | 13,837 | -2% | -$34,665 | ||||||
| D | 2018-06-25 | CRL | Charles River Laboratories International Inc | Massaro George | Dir | S - Sale+OE | $114.05 | -3,230 | 14,137 | -19% | -$368,381 | |||||
| M | 2018-06-21 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.04 | -5,441 | 5,746,081 | 0% | -$207,002 | |||||
| D | 2018-06-15 | IQV | Iqvia Holdings Inc. | Bousbib Ari | See Remarks | S - Sale+OE | $103.20 | -92,160 | 1,331,519 | -6% | -$9,510,912 | |||||
2018-06-15 | IQV | Iqvia Holdings Inc. | Cpp Investment Board Private Holdings, Inc. | 10% | S - Sale | $103.00 | -9,291,036 | 7,453,388 | -55% | -$956,976,708 | ||||||
2018-06-15 | IQV | Iqvia Holdings Inc. | Tpg Group Holdings (Sbs) Advisors, Inc. | Dir | S - Sale | $103.00 | -6,716,253 | 16,149,276 | -29% | -$691,774,059 | ||||||
2018-06-15 | IQV | Iqvia Holdings Inc. | Connaughton John | Dir | S - Sale | $103.00 | -1,441,236 | 3,815,315 | -27% | -$148,447,308 | ||||||
2018-06-14 | MEDP | Medpace Holdings, Inc. | Medpace Limited Partnership | 10% | S - Sale | $41.80 | -3,000,000 | 10,399,997 | -22% | -$125,400,000 | ||||||
2018-05-31 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $3.40 | -100 | 2,053,685 | 0% | -$340 | ||||||
2018-05-31 | EXEL | Exelixis, Inc. | Hessekiel Jeffrey | EVP, GC | S - Sale | $20.71 | -65,000 | 255,067 | -20% | -$1,346,150 | ||||||
| D | 2018-05-30 | EXEL | Exelixis, Inc. | Feldbaum Carl B | Dir | S - Sale+OE | $20.60 | -34,262 | 15,221 | -69% | -$705,797 | |||||
| D | 2018-06-01 | EXEL | Exelixis, Inc. | Schwab Gisela | Pres Prod Dev, Med Aff, CMO | S - Sale+OE | $20.80 | -22,500 | 292,793 | -7% | -$468,000 | |||||
| M | 2018-05-25 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $3.41 | -6,700 | 2,053,785 | 0% | -$22,841 | |||||
| D | 2018-05-23 | NRCI | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $33.88 | -5,066 | 26,894 | -16% | -$171,618 | |||||
| D | 2018-05-22 | EXEL | Exelixis, Inc. | Willsey Lance | Dir | S - Sale+OE | $21.40 | -50,000 | 418,273 | -11% | -$1,070,000 | |||||
| D | 2018-05-24 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $20.55 | -90,000 | 318,705 | -22% | -$1,849,500 | |||||
| DM | 2018-05-21 | NRCI | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $34.50 | -13,401 | 31,894 | -30% | -$462,295 | |||||
2018-05-21 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $3.40 | -915 | 2,060,485 | 0% | -$3,111 | ||||||
2018-05-22 | ELOX | Eloxx Pharmaceuticals, Inc. | Ward Robert | CEO | P - Purchase | $14.34 | +5,000 | 15,000 | +50% | +$71,700 | ||||||
| DM | 2018-05-18 | NRCI | National Research Corp | Berwick Donald M | Dir | S - Sale+OE | $34.54 | -25,309 | 0 | -100% | -$874,231 | |||||
| M | 2018-05-17 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $3.40 | -102,930 | 2,061,400 | -5% | -$349,962 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |